MI
MIRM.US Mirum Pharmaceuticals Inc
- Market cap
- USD 5.98B
- P/E
- -
- P/B
- 26.59x
- ROE
- -
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.
Is MIRM.US undervalued?
Graham numberThe Graham number of Mirum Pharmaceuticals Inc cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Mirum Pharmaceuticals Inc fundamental analysis
No fundamental analysis for Mirum Pharmaceuticals Inc yet.
Mirum Pharmaceuticals Inc stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Mirum Pharmaceuticals Inc
Mirum Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel therapies for debilitating rare and orphan diseases. Its lead product candidate is LIVMARLI (maralixibat), an orally administered and minimally absorbed ileal bile acid transporter (IBAT) inhibitor that is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome in the United States and internationally. The company is also involved …
Full company profileMirum Pharmaceuticals Inc financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Mirum Pharmaceuticals Inc annual financial statements (USD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||
| Revenue | 0.00 | 0.00 | 11.0M | 19.1M | 77.1M | 186M | 337M | 521M | 696M |
| Gross Profit | 0.00 | -324K | -623K | 17.2M | 64.7M | 139M | 255M | 421M | 570M |
| Operating Income | -2.92M | -54.7M | -104M | -173M | -131M | -109M | -87.6M | -22.1M | -221M |
| EBITDA | -13.0M | -54.4M | -102M | -65.4M | -123M | -136M | -49.0M | 17.2M | -1.10B |
| Net Income | -17.3M | -52.6M | -103M | -84.0M | -136M | -163M | -87.9M | -23.4M | -1.20B |
| EPS | -0.75 | -2.29 | -4.09 | -2.77 | -3.99 | -4.00 | -1.85 | -0.47 | -18 |
| Balance Sheet | |||||||||
| Total Assets | 52.0M | 147M | 241M | 295M | 353M | 647M | 671M | 843M | 1.03B |
| Total Liabilities | 62.3M | 16.4M | 68.8M | 174M | 211M | 398M | 445M | 528M | 1.08B |
| Shareholders' Equity | -10.3M | 130M | 172M | 120M | 142M | 249M | 226M | 315M | -54.2M |
| Cash & Short-term Investments | 52.0M | 117M | 232M | 157M | 152M | 286M | 280M | 383M | 374M |
| Total Debt | - | 3.65M | 3.26M | 2.61M | 2.19M | 308M | 318M | 319M | 744M |
| Cash Flow | |||||||||
| Operating Cash Flow | -373K | -39.4M | -89.1M | -133M | -120M | -70.9M | 10.3M | 55.8M | -675M |
| Capital Expenditure | 7.50M | 281K | 225K | 19.0M | 278K | 20.1M | 993K | 954K | 3.54M |
| Free Cash Flow | -7.87M | -39.6M | -89.3M | -152M | -120M | -91.1M | 9.33M | 54.9M | -678M |
| Ratios | |||||||||
| ROE | - | -40.3% | -60.0% | -69.9% | -95.5% | -65.7% | -39.0% | -7.4% | - |
| ROA | -33.4% | -35.8% | -42.9% | -28.5% | -38.4% | -25.3% | -13.1% | -2.8% | -116.6% |
| Net Profit Margin | - | - | -938.8% | -438.9% | -176.0% | -87.7% | -26.1% | -4.5% | -172.1% |
| Debt to Equity | - | 0.03x | 0.02x | 0.02x | 0.02x | 1.24x | 1.41x | 1.02x | - |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Mirum Pharmaceuticals Inc dividends
- Dividend yield
- -
- Forward dividend
- -
- Payout ratio
- -
- Ex-dividend date
- -
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2025 | - | - | - |
| 2024 | - | - | - |
| 2023 | - | - | - |
| 2022 | USD 5.55M | 0.16 | - |
| 2021 | - | - | - |
| 2020 | - | - | - |
| 2019 | - | - | - |
| 2018 | - | - | - |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Who owns Mirum Pharmaceuticals Inc
- Insiders 2.41%
- Institutions 97.59%
- Public & others 0.00%
- Shares outstanding 65.3M
- Free float 56.7M
Top funds holding MIRM.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| Vanguard MStar Total Stk Mkt Idx Invest | 1.77M | 2.72% | +7.28% | Sep 2026 |
| T. Rowe Price Health Sciences | 1.57M | 2.41% | 0.00% | Sep 2026 |
| Strategic Advisers Fidelity US TtlStk | 1.49M | 2.28% | +10.85% | Sep 2026 |
| State Street® SPDR® S&P® Biotech ETF | 1.32M | 2.02% | +2.68% | Oct 2026 |
| Vanguard Small Cap Index | 1.24M | 1.90% | +4.00% | Sep 2026 |
| iShares Russell 2000 ETF | 1.20M | 1.84% | 0.00% | Oct 2026 |
| American Funds SMALLCAP World A | 1.12M | 1.72% | 0.00% | Sep 2026 |
| Polar Capital Biotech S Inc | 801K | 1.23% | 0.00% | Sep 2026 |
| Eventide Gilead N | 709K | 1.09% | 0.00% | Jun 2026 |
| Vanguard MStar Small Cap Growth Indx Inv | 692K | 1.06% | +1.02% | Sep 2026 |
| Janus Henderson Triton D | 689K | 1.06% | 0.00% | Sep 2026 |
| Janus Henderson Global Life Sciences D | 658K | 1.01% | 0.00% | Sep 2026 |
| Janus Global Life Science AUSD | 647K | 0.99% | +3.10% | Sep 2026 |
| T. Rowe Price New Horizons | 637K | 0.98% | -11.03% | Sep 2026 |
| Janus Henderson Glb Life Scn I2 USD | 632K | 0.97% | +21.22% | Aug 2026 |
| Invesco Discovery A | 606K | 0.93% | +10.04% | Sep 2026 |
| Fidelity Small Cap Growth | 564K | 0.86% | 0.00% | Aug 2026 |
| Eventide Healthcare & Life Sciences I | 530K | 0.81% | -23.25% | Jun 2026 |
| Fidelity Small Cap Index | 520K | 0.80% | +0.15% | Aug 2026 |
| Janus Henderson Hrzn Biotec E2 USD | 494K | 0.76% | -16.21% | Jun 2026 |
Top institutions holding MIRM.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| Frazier Life Sciences Management, L.P. | 7.68M | 11.76% | 0.00% | Jun 2026 |
| Jupiter Topco LLC | 5.91M | 9.05% | 0.00% | Jun 2026 |
| BlackRock Inc | 4.39M | 6.72% | +14.13% | Jun 2026 |
| FMR Inc | 3.67M | 5.62% | +86.75% | Jun 2026 |
| T. Rowe Price Associates, Inc. | 2.66M | 4.07% | +54.63% | Jun 2026 |
| Vanguard Portfolio Management, LLC | 2.38M | 3.64% | +65.98% | Jun 2026 |
| Vanguard Capital Management, LLC | 2.25M | 3.45% | -6.65% | Jun 2026 |
| State Street Corp | 2.17M | 3.33% | +11.64% | Jun 2026 |
| William Blair Investment Management, LLC | 1.40M | 2.15% | +318.49% | Jun 2026 |
| Geode Capital Management, LLC | 1.39M | 2.14% | +10.63% | Jun 2026 |
| Amvescap Plc. | 1.36M | 2.09% | +378.23% | Jun 2026 |
| Wellington Management Company LLP | 1.31M | 2.01% | -1.86% | Jun 2026 |
| Eventide Asset Management, LLC | 1.25M | 1.91% | -11.39% | Jun 2026 |
| TANG CAPITAL MANAGEMENT LLC | 1.24M | 1.89% | 0.00% | Jun 2026 |
| Capital World Investors | 1.15M | 1.77% | +59.23% | Jun 2026 |
| Franklin Templeton Inc | 1.15M | 1.77% | +61.27% | Jun 2026 |
| Novo A/S | 1.13M | 1.72% | -15.09% | Jun 2026 |
| TCG Crossover Management, LLC | 1.06M | 1.63% | 0.00% | Jun 2026 |
| Bvf Inc | 1.06M | 1.62% | -33.36% | Jun 2026 |
| Polar Capital Holdings PLC | 846K | 1.30% | +198.26% | Jun 2026 |
Mirum Pharmaceuticals Inc company profile
- Company name
- Mirum Pharmaceuticals Inc
- Ticker
- MIRM.US
- Exchange
- USA Stocks
- Listed since
- Jul 18, 2019
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 470
- Fiscal year end
- December
- Address
- 989 East Hillsdale Boulevard, Foster City, CA, United States, 94404
- Phone
- 650 667 4085
- Website
- mirumpharma.com
About Mirum Pharmaceuticals Inc
Mirum Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel therapies for debilitating rare and orphan diseases. Its lead product candidate is LIVMARLI (maralixibat), an orally administered and minimally absorbed ileal bile acid transporter (IBAT) inhibitor that is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome in the United States and internationally. The company is also involved in the commercialization of Cholbam, a cholic acid capsule, which is approved as treatment for pediatric and adult patients with bile acid synthesis disorders due to single enzyme defects and for adjunctive treatment of patients with peroxisomal disorders, including peroxisome biogenesis disorder-Zellweger spectrum disorder and Smith-Lemli-Opitz syndrome; and Chenodal, a tablet, which is approved for the treatment of radiolucent stones in the gallbladder, and under development for the treatment cerebrotendinous xanthomatosis. In addition, it develops Volixibat, an oral and minimally absorbed agent designed to inhibit IBAT, currently under Phase 2b clinical trial for the treatment of adult patients with cholestatic liver diseases; Brelovitug, for the treatment of chronic HDV infection, which is in Phase 2 clinical trial; and MRM-3379, that is in Phase 2 clinical study for the treatment of FXS. The company has a collaboration agreement with the Shire International GmbH; License Agreement with Pfizer Inc.; Sanofi-Aventis Deutschland GmbH; Novartis Pharma AG; Lonza Ltd.; Enthorin Therapeutics, LLC and Dart Neuroscience LLC; Asset Purchase Agreement with Asklepion Pharmaceuticals, LLC; License and Manufacturing Agreement with LGM Pharma; and Asset Purchase Agreement with Travere Therapeutics, Inc. The company was incorporated in 2018 and is headquartered in Foster City, California.
Mirum Pharmaceuticals Inc management
10- Mr. Christopher PeetzCEO & Director · born 1979
- Mr. Peter Radovich M.B.A., Ph.D.COO & President · born 1978
- Mr. Eric H. Bjerkholt M.B.A., M.S.Chief Financial Officer · born 1960
- Dr. Jean-Luc Girardet Ph.D.Chief Technical Officer
- Mr. Andrew McKibbenSenior Vice President, Strategic Finance & Investor Relations
- Mr. Douglas T. Sheehy J.D.Chief Legal Officer & Secretary · born 1967
- Meredith KiernanSenior Director of Global Corporate Communications
- Ms. Erin CampanyChief People Officer · born 1968
- Ms. Lara Longpre MBA, MSCChief Development Officer · born 1970
- Ms. Vinita P. KumarSenior Vice President of Quality